At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 144 enrolled
Drug / intervention
SHR-1209 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentric, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 in Patients With Hypercholesterolemia
In Brief
A Phase 3 clinical trial evaluating SHR-1209 and SHR-1209 Placebo for Primary Hypercholesterolemia. Completed, enrolled 144 participants across 1 site.
Detailed Summary
This study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hypercholesterolemia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionAug 2022
TodayJul 2026
First PostedApr 14, 2021
Enrollment StartApr 14, 2021
Primary CompletionAug 12, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.2 years ago
Interventions
SHR-1209drug
SHR-1209
SHR-1209 Placebodrug
SHR-1209 Placebo